All In MedTech

Device Trial Radar · NCT05227365

Treatment Evaluation of Neuromodulation for Tinnitus - Stage A3

Treatment Evaluation of Neuromodulation for Tinnitus - Stage A3 (TENT-A3)

Last checked: Nov 20, 2026Latest source record: Dec 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

112

Actual

Start

Mar 21, 2022

Primary completion

Sep 6, 2022

Study completion Oct 25, 2022

Sponsor

Lead sponsor
Neuromod Devices Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
BRAI3N (clinical site), Belgium; St. James's Hospital, Ireland; German Hearing Center Hannover (clinical site), Germany; Avania (CRO/project manager), Netherlands
First posted
Feb 7, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TENT-A3 is a single arm repeated measures prospective investigation evaluating the safety and efficacy of the Lenire device for tinnitus treatment. The Lenire device provides non-invasive bimodal (sound and tongue) stimulation to alleviate the symptoms of chronic, subjective tinnitus. Participants presenting to one of the several study sites with a diagnosis of chronic subjective tinnitus who meet the inclusion criteria are enrolled in the investigation while the study site is active. The objective of TENT-A3 is to determine whether the addition of tongue stimulation to sound-only stimulation provides additional clinically significant improvements in tinnitus symptoms beyond that of the sound-only stimulation component of the bimodal treatment.

Conditions

  • Tinnitus

Interventions

  • LenireDevice

    The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tinnitus Handicap Inventory (THI)Time frame: Enrollment visit to final visit (Week 0 to Week 12)

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • BRAI3N

    Ghent, Belgium

  • German Hearing Center

    Hanover, Germany

  • The Wellcome HRB Clinical Research Facility at St. James's Hospital

    Dublin, Ireland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.